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It has been stated, that the administration of Dexamethasone has an impact on the morbidity 
following tonsillectomy.
Objective: To re-calculate the blood values for Dexamethasone when given as fixed doses and 
to evaluate the effect of Dexamethasone on post-operative nausea, vomiting and bleeding rates 
following tonsillectomy.
Materials and methods: The charts of 272 children (2-15 years) who had undergone tonsillectomy 
were analyzed. The rates of post-operative nausea, vomiting and bleeding in relation to Dexamethasone 
were calculated-in general and different doses (0 mg/kg, <0.15 mg/kg, >0.15 mg/kg).
Study design: Retrospective cohort study.
Results: Dexamethasone was administered in 121 children (43.7%) according to the preference of 
the anesthesist (mean dose: 0.2 +/- 0.12 mg/kg; range: 0.04 - 0.62 mg/kg). There was no significant 
difference in nausea and vomiting (p=0.953) or bleeding (p=0.827) across groups receiving or not 
receiving Dexamethasone. Stratification into three different groups of Dexamethasone concentration 
also did not identify a dose-related risk of postoperative nausea or vomiting (p=0.98) or bleeding 
(p=0.71).
Conclusion: At least under common non-controlled conditions in the clinic, Dexamethasone does 
not appear to have an effect on nausea or vomiting or bleeding following tonsillectomy.
ORIGINAL ARTICLE
Braz J Otorhinolaryngol.
2011;77(3):373-9. BJORL
Keywords: 
dexamethasone,
hemorrhage,
postoperative 
complications,
tonsillectomy.
.org
374
Brazilian Journal of otorhinolaryngology 77 (3) May/June 2011
http://www.bjorl.org  /  e-mail: revista@aborlccf.org.br
INTRODUCTION
Several meta-analyses investigating morbidity 
following tonsillectomy have demonstrated that under 
controlled conditions a single intravenous dose of Dexame-
thasone (DX) is an effective, safe and inexpensive method 
of reducing the incidence of postoperative nausea and 
vomiting (PONV) following tonsillectomy in children1-5. 
Unfortunately, there is substantial variability across these 
studies with respect to design, surgical technique, method 
of acquiring hemostasis and age of patients. Recently, Czar-
netky et al6 identified a dose-dependent increased rate of 
post-tonsillectomy hemorrhage following administration of 
DX. In their study, 50 children were given either a placebo 
or one of three different concentrations of DX (0.05, 0.15 
or 0.5 mg/kg). None of the children in the placebo group 
required surgical intervention for hemostasis, whereas chil-
dren in all other DX groups required surgical intervention 
for hemostasis (5.7%; 2%; 8%, respectively). 
At the primary investigator’s institution, the decision 
to administer DX during tonsillectomy is determined by the 
personal anesthetist’s preference. The goal of the present 
study was to determine the effect of DX on PONV and 
bleeding following tonsillectomy from a clinical situation 
thus maybe better mimic what effect routinely given De-
xamethasone would have in ordinary praxis. We therefore 
calculated the exact blood values for DX related to the 
individual patient´s weight in this study to clarify, whether 
or not the values vary significantly in this patient popu-
lation. This would limit the value of conclusions drawn 
from studies with administration of DX in fixed doses. 
Moreover, we hypothesized that the administration of DX 
would result in a lower rate of PONV but not to cause an 
increased rate of bleeding.
MATERIAL AND METHODS
The study was in accordance with the require-
ments of the associated IRB. The charts of 385 continuous 
pediatric patients (age < 15 years) who had undergone 
tonsillectomy, with or without adenoidectomy between 
January 2008 and December 2009 were reviewed. Children 
who had undergone partial (intracapsular) tonsillectomy 
(n=108) or who had received methylprednisolone instead 
of DX (n=5) were excluded from the analysis. Included 
patients (n=272) were otherwise healthy without a predis-
position to bleeding, such as immunodeficiency, diabetes, 
gastritis, peptic ulcer, cardiovascular, arterial hypertension, 
malignant or renal diseases or on therapy with corticoids, 
anti-emetics, anti-histaminics or aspirin.
Patients were premedicated with oral midazolam 0.5 
mg/kg 20 minutes before transportation to the operating 
theatre. All procedures were performed under general 
anesthesia with oral intubation. Anesthesia was induced 
with one of three volatile agents (isoflurane, sevoflurane, 
desflurane). An intravenous line was placed and lactated 
Ringer´s solution infused after the eyelash reflex had di-
sappeared. Endotracheal intubation was facilitated by 0.1 
mg/kg pancuronium. All children received paracetamol 15 
mg/kg per rectum. Fentanyl was given according to the 
preference of the anesthesist. Anesthesia was maintained 
with volatile agents or propofol with oxygen and N
2
O. 
Adrenalin-containing local anesthetic agents were never 
used intraoperatively. Tonsillectomies were performed 
using a cold technique, dissecting the tonsils with scissors, 
raspatory and removing the inferior pole with a snare. 
Hemostasis was obtained with suture ligation and bipolar 
cautery where required. DX was administered per each 
anesthetist’s preference on a case-by-case basis. Patients 
were given either one half (4 mg) or a full (8 mg) vial 
of DX. The dose of DX administered was retrospectively 
calculated for each patient (mg/kg).
Children were extubated in the operating theatre 
and then transported to the postanesthesia care unit when 
they were awake and responded to verbal stimuli. They 
were closely monitored for 2 hours and transported to the 
ward when vital signs were stable, pain was controlled, 
and they did not have vomiting or bleeding. Piritramid was 
administered in 103 children on demand for additional 
pain control in the postoperative care unit.
Patients were admitted for approximately four days. 
Episodes of PONV and bleeding were documented. 
Statistical analysis was carried out using SPSS statis-
tical package (SPSS 16.0.2 for Windows). Non-parametric 
data were analyzed using Chi-square-test for categorical 
data and Mann-Whitney-U-test for continuous data with 
significance determined as p <0.05. In addition to inves-
tigating the effect of previously reported cut-off doses of 
DX on PONV and bleeding following tonsillectomy, we 
attempted to determine a cut-off dose of DX above which 
the risk of PONV or bleeding was increased.
RESULTS
There were 272 children included in this study (129 
male, 143 female). The mean age of patients was 7.43 +/-
4.3 years (range 2 - 15 years). DX was administered to 121 
(43.7%) children either as one half or a full vial. The mean 
dose of DX given (calculated retrospectively based on 
weight) was 0.2 +/- 0.12 mg/kg (range 0.04 - 0.62 mg/kg). 
Five children who were excluded from this study received 
methylprednisolone in high doses (100 or 250 mg) instead 
of DX. Nausea or vomiting was experienced by 62 of 272 
(22.8%) patients, 28 of whom (45.2%) had received DX. 
There was no significant difference in nausea or vomiting 
across groups receiving or not receiving DX (p=0.953). 
Further analysis revealed that 6 of 272 patients (2.2%) had 
nausea without vomiting, 4 of whom had received DX 
(doses were 0.05, 0.12, 0.15 and 0.17 mg/kg). There was 
no difference in nausea across groups receiving or not 
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receiving DX (Chi-square test, p=0.827). 56 of 272 patients 
(20.6%) had vomiting without nausea, 24 of whom (42.9%) 
had received DX (mean dose 0.16 +/-0.09 mg/kg, range 
0.07 - 0.44 mg/kg). There was no difference in vomiting 
across groups receiving or not receiving DX (Chi-square 
test, p=0.953). Evaluation of the effect of DX dose (0 vs. 
<0.15 vs. ≥0.15 mg/kg) on postoperative nausea or vomi-
ting did not reveal a difference across groups (Chi-square 
test, p=0.98; Table 1 and 2). 79 children received fentanyl 
1μg/kg while 198 children did not. Anesthesia was main-
tained with volatile agents and oxygen as single agents to 
maintain anesthesia in 135 children with (n=220) or without 
(n=57) N
2
O. Maintenance of anesthesia was achieved with 
propofol in 142 patients, with (n=118) or without (n=24) 
volatile agents, again, with (n=98) or without (n=44) N
2
0. 
229 of the 272 children received piritramid perioperatively, 
of whom 104 had received DX (45.4%). Piritramid was not 
administered in 48 of the 272 patients of whom 22 had 
received DX (45.8%). The effect of DX to prevent nausea 
was statistically insignificant (p=0.827; Chi-square-test). 
There was no significant association of postoperative nau-
sea and/or vomiting and anesthetic drugs such as fentanyl 
(p=0.07), piritramid (p=0.026) or N
2
0 (p=0.406).
Hemorrhage from the tonsillectomy site occurred 
in 22 patients, surgical intervention was required in 17 of 
272 patients (6.3%), 7 of whom (41.2%) had received DX 
(table 3). Primary bleeding (<24 h) was documented in 7 
cases and secondary bleeding (>24 h) in 10 children. Two 
children had more than one episode of secondary bleeding 
(postoperative day 7/12 and 8/10, respectively). One of 
these children had received 0.15 mg DX/kg, the second 
no DX. There was no difference in post-tonsillectomy 
hemorrhage across groups receiving or not receiving DX 
(p=0.827). Evaluation of the effect of DX dose on posto-
perative tonsillectomy hemorrhage did not identify a dose-
related risk of postoperative bleeding (p=0.711; table 4). 
We were unable to determine a cut-off dose of DX above 
which the risk of PONV or bleeding was increased due to 
the large variability of DX doses administered. 
DISCUSSION
Previous studies investigating the effect of intrave-
nously administered DX on nausea and vomiting following 
tonsillectomy have found promising results2,6-20 In these 
studies, DX was most commonly administered as a single 
intravenous dose before tonsil dissection. In these studies, 
administered doses were 421, 822,1023 or 20 mg24 or the doses 
were related to the body weight ranging from 0.1525-27, 0.56, 
13, 14, 18, 19, 28, 29, 0.730 to 17, 9, 10, 17, 31, 32 mg/kg. In some studies, 
a dose of 811, 13, 26, 29, 33, 1010, 1228, 34, 1531, 169, 19, 206, 257, 30, 
2432 or 50 mg17 was injected with the additional goal of 
reducing post-tonsillectomy pain6, 7, 9, 10, 12, 14-17, 19, 20, 22, 24, 25, 
35-38. Unfortunately, there is great variability across studies, 
making it difficult to draw any conclusions.
Czarnetzki et al were the first to report a dose-
related increased risk of post-tonsillectomy hemorrhage 
following the administration of DX.6 Patients in this study 
Table 1. Age distribution in three subpopulations according to 
specified DX values
age (years) no DX
DX < 0,15 
mg/kg
DX ≥ 0,15 
mg/kg
total
1 1 (50%) 0 (0%) 1 (50%) 2
2 7 (70%) 2 (20%) 1 (10%) 10
3 23 (55%) 12 (26%) 7 (19%) 42
4 25 (63%) 12 (30%) 3 (7%) 40
5 19 (48%) 12 (30%) 9 (22%) 40
6 6 (35%) 6 (35%) 5 (30%) 17
7 6 (46%) 4 (31%) 3 (23%) 13
8 5 (36%) 2 (14%) 7 (50%) 14
9 7 (63%) 3 (27%) 1 (10%) 11
10 2 (25%) 3 (38%) 3 (37%) 8
11 4 (50%) 2 (25%) 2 (25%) 8
12 5 (42%) 6 (50%) 1 (8%) 12
13 5 (50%) 5 (50%) 0 (0%) 10
14 15 (68%) 4 (18%) 3 (14%) 22
15 21 (91%) 2 (9%) 0 (0%) 23
total
n=151 
(55%)
n=75 
(28%)
n=46 
(17%)
n=272
Three subgroups were compared according to the calculated concen-
tration of dexamethasone vs. age.
Table 2. Incidence of PONV with specified DX values
no DX
DX< 0,15 mg/
kg
DX≥ 0,15 mg/
kg
mean 
(mgDX/kg)
0 0.10 0.26
median 
(mgDX/kg)
0 0.11 0.20
std
(±mgDX/kg)
0 0.03 0.13
min; max
(mgDX/kg)
0 0.04; 0.14 0.15; 0.62
∅ PONV 117 (77%) 58 (77%) 35 (78%)
PONV 34 (23%) 17 (23%) 11 (22%)
total n=151 n=75 n=4
Comparison of the three subgroups 0 vs. <0.15 and >0.15 mg/kg 
could not identify a dose-related risk of or nausea and vomiting that 
reached statistical significance (p=0.98).
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somewhat artificial conditions of contemporary studies, 
our case-controlled study evaluated outcomes following 
tonsillectomy under common clinical conditions. Becau-
se guidelines regarding the administration of DX are not 
yet standardized at our institution and the decision to 
administer DX is at the discretion of the anesthetist, a 
retrospective case-controlled study could be conducted. 
The present study included 272 children with a 
mean age of 7.43 years which compares to the ma-
jority of studies published in the literature (table 4). 
When administered, the mean dose of DX was 0.2 mg/
kg with a range of 0.04 to 0.62 mg/kg per dose. Those 
authors20-24 who administered DX not in relation to weight 
but as a fixed dose did not calculate the effective dose. 
The results of the present study indicate that the effec-
tive dose is significantly influenced by weight even in a 
pediatric population which compounds comparison with 
more sophisticated studies. The median effective dose of 
0.2 mg/kg may be lower than calculated in most of the 
studies (table 4). However, evidence has been given, that 
higher blood concentrations are not associated with an 
increased benefit32.
The rate of PONV in the present study was 23% 
with or without DX. This rate is lower than reported in 
comparable groups (table 5). There was no difference in 
nausea or vomiting across groups receiving or not receiv-
ing DX in the present study. This finding is supported by a 
number of well-designed prospective studies25, 28, 37, 39, 40 and 
refuted by others25, 28, 37, 39, 40. For example, results contrast 
with Karaman who found a dose-dependent decrease in 
PONV rates following administration of DX30. Even though 
DX dose levels in the present study (0.62 mg/kg) did not 
attain concentrations of as high as those administered by 
Karaman (0.7 mg/kg), doses in the present study were 
close enough that one would expect to see some effect. 
This reasoning is supported by Kim et al31 who verified in 
a double-blinded, prospective randomized study on 125 
children that DX doses of 0.0625 mg/kg, 0.125, 0.25, 0.5 
and 1 mg/kg are equally effective in reducing PONV rates.
The post-tonsillectomy hemorrhage rate requir-
ing surgical intervention in the present study was 6.3%. 
When the five patients who experienced minor episodes 
of bleeding were included, the post-tonsillectomy bleed 
rate increased to 8.1%. Rates in the literature vary sig-
nificantly (table 4) which may also result from different 
surgical techniques, length of follow-up and definitions 
of post-tonsillectomy hemorrhage. The rate of post tonsil-
lectomy hemorrhage in the present study is higher than 
reported previously41, 42 which appears attributable to the 
use of electrosurgery either for dissection or hemostasis. 
There was no difference in post-tonsillectomy hemorrhage 
rates across groups receiving or not receiving DX in the 
present study which is only partly supported by other 
authors (table 4).
Table 3. Post-tonsillectomy hemorrhage vs. DX doses
Patient age DX (mg/kg) PONV PTH (day)
1. 4 0,4  day of surgery
2. 3 0,11  day of surgery
3. 15 0  day of surgery
4. 9 0 Yes day of surgery
5. 5 0  day of surgery
6. 4 0,14  day of surgery
7. 8 0  day of surgery
8. 14 0  1.
9. 5 0,09  2. 
10. 7 0,09  3.
11. 13 0,061  3.
12. 8 0  3.
13. 11 0  5.
14. 9 0  6. 
15. 3 0 Yes 7.+12. 
16. 3 0,15  8.+10. 
17. 8 0  9.
18. 12 0.19  8.*
19. 14 0  1.*
20. 15 0  1.*
21. 3 0.62  7.*
22. 6 0.15  5.*
DX=dexamethasone; PONV=postoperative nausea and vomiting; 
PTH=post-tonsillectomy hemorrhage; *=no surgical intervention 
required
Table 4. Incidence of postoperative bleeding with specified 
DX values
no DX
DX< 0,15 mg/
kg
DX≥ 0,15 mg/
kg
Uneventful 139 (92%) 70 (93%) 41 (89%)
postoperative 
bleeding
12 (8%) 5 (7%) 5 (11%)
Total n=151 n=75 n=46
Stratification into three different groups of DX concentration (0 vs. <0.15 
and >0.15 mg/kg) could not identify a dose-related risk of postoperative 
bleeding (p=0,711).
received a placebo or one of three different concentra-
tions of DX (0.05; 0.15 or 0.5 mg/kg). Due to the large 
variability in dose of DX administered in the present 
study, we decided first to determine if there was any 
effect of DX on PONV or bleeding, and then investigate 
the dose-response relation of DX using similar cut-off va-
lues similar to those used by Czarnetzki (0 mg/kg, <0.15 
mg/kg, >0.15 mg/kg). In contrast to standardized but 
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Table 5. Post-tonsillectomy hemorrhage and vomiting in the literature (sorted by date)
Author
age
(DX; control 
group)
N
(DX; control 
group)
bleeding rate
(DX; control 
group)
PONV rate
(DX; control 
group)
DX dose dissection technique
hemostasis 
technique
Catlin44 4-6; 5-12 10; 15 20%; 6,7% ns  8 mg/m2  cold E
Volk23 6.9; 7.0 25; 24 8.0%; 4.2% ns 10 mg cold E
Tewary45 22; 21 (median) 40; 42 0% ns 4 mg cold suture ligation
Fields22 24.7; 23.7 29; 29 0% ns 8 mg cold suture ligation
Ohlms28 7.0; 6.9 34; 35 8.8%; 0% 35%, 43% 0.5 mg/kg; max. 12 mg cold E
Splinter26 6.9; 6.9 63; 70 0% 40%; 71% 0.15 mg/kg;max. 8 mg ns ns
April9 6.5; 7.2 41; 39 2.4%; 2.6% 4.8%; 25.6% 1 mg/kg; max. 16 mg E E
Tom10 1-18 (mean: 5.64) 26; 32 3.8%; 6.3% 4%; 48%
 1 mg/kg; max. 
10 mg  E E
Pappas7 6.0; 5.8 63; 65 0% 48%; 88%  1 mg/kg; max. 25 mg E E
Carr24 26.9; 27.6 15; 14 6.7%; 14.3% ns 20 mg E E
Vosdoganis11 5.0; 5.7 22;19 0% 45%; 63%  0.4 mg/kg; max. 8 mg ns ns
Aouad13 5.1; 4.6 53; 53 0% 23%; 51% 0.5 mg/kg; max. 8 mg E E
Stewart46 >16 104; 48 17.3%; 27.1% 23%; 30%
 8 mg  , 2 mg 
postop; 2x2 
mg day 1-4; 2 
mg day 5-8
E ns
Giannoni47 (3-15) 25; 25 8%; 4% 28%; 36% 1.0 mg/kg; max. 16 mg E after LA E
Elhakim33 5.2; 5.1 55; 55 0% 20%; 56% 0.5 mg/kg; max. 8 mg E E
Al-Shehri16 18-35 15; 15 0% 0%; 13% 3 x 8 mg/24 h E E
Hanasono17 5.7; 5.9 106; 113 2.8%; 0.9%
1.2; 2.1 
episodes of 
emesis
1 mg/kg; max. 
50 mg 
E
E
cold
Celiker48 5.3; 6.1; 5.9 vs. 5.8
26; 27; 
24 vs. 25 0%
27%; 37%; 29% 
vs. 36%
0.15; 0.1; 0.05 
vs. 0 mg/kg; 
max. 8 mg
cold suture ligation
Samarkandi18 7.2; 7.2 29; 31 0% 37.9%; 74.2%  0.,5 mg/kg  E E
Malde25 12; 15 45; 45 0%; 1.1% 22%; 29% 0.15 mg/kg cold suture ligation
McKean20 23; 26 24; 22 0% 29%; 77%  10 mg cold suture ligation
Kaan19 7.6; 9.3 32; 30 0% 19%; 33% 0.5 mg/kg; max. 16 mg cold suture ligation
Fazel29 9.5; 10.1 50; 50 0% 25%; 62 0.5 mg/kg; max. 8 mg  ns ns
Czarnetzki6 6; 5; 6 vs. 6 (median)
53; 54;
52 vs. 54
11%; 4%; 24% 
vs. 4%
38%; 24%; 12% 
vs.44%
0.05; 0.15; 0.5 
vs. 0 mg/kg; 
max. 20 mg
cold or E 
after LA
suture ligation 
or E
Karaman30 (5.9) 100; 50 0% 8%; 4%; 80%
0.2 mg/kg; 0.7 
mg/kg; max. 
25 mg
ns ns
this study 7.0; 7.78 126; 151 7.9%; 7.9% 22.5%; 22.2% 2 mg (<20 kg)4 mg(>20 kg) cold suture ligation
E=electrosurgery; cold=dissection of the tonsils with raspatory, scissors; LA=local infiltration of local anesthetics prior to tonsil dissection; 
ns=not stated; age in brackets indicates that ages of the subgroups were specified;
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Postoperative vomiting was associated in only 1 of 
the 22 cases with major bleeding (5.4%) and in no case 
with minor bleeding suggesting that vomiting itself is not 
likely a risk factor for post-tonsillectomy hemorrhage. 
This contrasts with previous reports of vomiting leading 
to excessive hemorrhage43.
The present study has some limitations which have 
to be considered. First, it is a retrospective observational 
study. Although it reports from a clinical situation and thus 
maybe better mimic what effect routinely given Dexameth-
asone would have in ordinary praxis its weakness is, that 
other factors that can influence PONV are not controlled. 
However, multivariate ANOVA-analysis was unable to de-
tect dexamethasone or one of the various anesthetic agents 
as a risk factor for PONV in our study population (data 
not shown).Second, the large amount of variability in the 
dose of DX administered. In an attempt to overcome this 
limitation, doses of DX were stratified into three groups for 
analysis. Even though stratification values were selected 
based on previously reported values, analysis based on 
different cut-off values may yield different results. We were 
unable to determine a cut-off dose of DX above which the 
risk of PONV or bleeding was increased due to the large 
variability of DX doses administered.
CONCLUSION
The administration of fixed doses of Dexametha-
sone results in significant differences of blood values (fac-
tor 15.5). At least under non-controlled conditions in the 
clinic, Dexamethasone appears not to have an effect on 
nausea or vomiting or bleeding following tonsillectomy. 
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